Psoralen-modified clamp-forming antisense oligonucleotides reduce cellular c-Myc protein expression and B16-F0 proliferation

Nucleic Acids Research

Volumn 29, Issue 19, 2001, Pages 4052-4061

  Stewart, Delisha A ^a   Thomas, Shelia D ^b   Mayfield, Charles A ^a   Miller, Donald M ^b  

^a University of Alabama at Birmingham   (United States)

^b University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AMINO ACID; ANTISENSE OLIGONUCLEOTIDE; MESSENGER RNA; MONOCLONAL ANTIBODY; MYC PROTEIN; OLIGODEOXYNUCLEOTIDE DERIVATIVE; PROTEIN INHIBITOR; PSORALEN; PURINE DERIVATIVE;

AMINO ACID SEQUENCE; ANIMAL CELL; ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONJUGATION; CONTROLLED STUDY; GEL MOBILITY SHIFT ASSAY; GROWTH CURVE; GROWTH INHIBITION; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MELANOMA B16; MELANOMA CELL; MOUSE; NONHUMAN; ONCOGENE C MYC; PRIORITY JOURNAL; PROTEIN CONTENT; PROTEIN DENATURATION; PROTEIN EXPRESSION; PROTEIN INTERACTION; PROTEIN PROCESSING; PROTO ONCOGENE; SEQUENCE ANALYSIS; ULTRAVIOLET RADIATION;

EID: 0035477235     PISSN: 03051048     EISSN: None     Source Type: Journal    
DOI: 10.1093/nar/29.19.4052     Document Type: Article

References (52)

1. The regulation and expression of c-myc in normal and malignant cells
2. Myc function and regulation
3. Inhibition of in vitro transcription by a triplex-forming oligonucleotide targeted to human c-myc P2 promoter
4. The myc oncogene: Its role in transformation and differentiation
5. Cellular oncogenes and retroviruses
6. C-myc proto-oncogene expression and prognosis in early carcinoma of the uterine cervix
7. Alterations to either c-erb B-2(neu) or c-myc proto-oncogenes in breast carcinomas correlate with poor short-term prognosis
8. Elevated expression of the c-myc oncoprotein correlates with poor prognosis in head and neck squamous cell carcinoma
9. Measurement of c-myc oncoprotein provides an independent prognostic marker for regional metastatic melanoma
10. Selection of successive tumour lines for metastasis
11. Molecular recognition by circular oligonucleotides: Increasing the selectivity of DNA binding
12. Oligonucleotide clamps arrest DNA synthesis on a single-stranded DNA target
13. Psoralens as photoactive probes of nucleic acid structure and function: Organic chemistry, photochemistry and biochemistry
14. Intramolecular DNA triplexes in supercoiled plasmids. I. Effect of loop size on formation and stability
15. Complex formation between polycytidylic acid and guanine oligonucleotides
16. Solvent, pH and ionic effects on the binding of single-stranded DNA by circular oligodeoxynucleotides
17. Recognition of RNA by triplex formation: Divergent effects of pyrimidine C-5 methylation
18. Single-stranded DNA as a target for triplex formation
19. Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides
20. Nucleotide sequence comparison of normal and translocated murine c-myc genes
21. Modulation of ras expression by anti-sense, nonionic deoxyoligonucleotide analogs
22. Efficient delivery of triplex forming oligonucleotides to tumor cells by adenovirus-polylysine complexes
23. Effects of c-myc expression on cell cycle progression
24. Sequence-specific photo-induced cross-linking of the two strands of double-helical DNA by a psoralen covalently linked to a triple helix-forming oligonucleotide
25. Covalent crosslinks introduced via a triple helix-forming oligonucleotide coupled to psoralen are inefficiently repaired
26. Spectroscopic studies of chimeric DNA-RNA and RNA 29-base intramolecular triple helices
27. Spectroscopic and calorimetric investigation on the DNA triplex formed by d(CTCTTCTTTCTTTTCTTTCTTCTC) and d(GAGAAGAAAGA) at acidic pH
28. The clinical significance of oncogene expression in subungual melanoma
29. Antisense oligonucleotides as therapeutic agents: Is the bullet really magical?
30. Myb targeted therapeutics for the treatment of human malignancies
31. Gene therapy for HIV infection
32. Gene and other biological therapies for vascular diseases
33. Pharmacological approaches in the treatment of primary hyperoxaluria
34. Identification and development of new biopharmaceuticals
35. Control of c-myc regulation in normal and neoplastic cells
36. c-myc antisense oligonucleotides inhibit the colony-forming capacity of Colo 320 colonic carcinoma cells
37. Enhancement of sensitivity of urinary bladder tumor cells to cisplatin by c-myc antisense oligonucleotide
38. Antisense c-myc and immunostimulatory oligonucleotide inhibition of tumorigenesis in a murine B-cell lymphoma transplant model
39. Antisense strategy in hematological malignancies
40. A modest reduction in c-Myc expression has minimal effects on cell growth and apoptosis but dramatically reduces susceptibility to Ras and Raf transformation
41. Effects of c-myc expression on proliferation, quiescence and G0 to G1 transition in nontransformed cells
42. Effects of c-myc expression on cell cycle progression
43. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination
44. Use of retroviral vectors for gene transfer and expression
45. Dependence of cyclin E-cdk2 kinase activity on cell anchorage
46. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2 and phosphorylation of the retinoblastoma protein
47. Structural effects in the recognition of DNA by circular oligonucleotides
48. Stabilities of nucleotide loops bridging the pyrimidine strands in DNA pyrimidine·purine·pyrimidine triplexes: Special stability of the CTTTG loop
49. Base pairing and steric interactions between pyrimidine strand bridging loops and the purine strand in DNA pyrimidine·purine·pyrimidine triplexes
50. Effect of 5-methylcytosine on the stability of triple-stranded DNA-a thermodynamic study
51. Control of gene expression by triple helix-forming oligonucleotides. The antigene strategy